



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcom Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherstone Michael V. Messinger Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Jeffrey T. Helvey Heldi L. Kraus Albert L. Ferro* Donald R. Banowit Peter A. Jackman Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono Virgil Lee Beaston Theodore A. Wood Joseph S. Ostroff Frank R. Cottingham Christine M. Unulier Rae Lynn P. Guest George S. Bardmesser Daniel A. Kleir Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller* LuAnne M. DeSantis Ann E. Summerfield Aric W. Ledford* Helene C. Carlson Timothy A. Doyle* Gaby L. Longsworth Lori A. Gordon* Nicole D. Dretar*

am Jyoti C. Iyer*
er Laura A. Vogel
erser Registered Patent Agents*
G Nancy J. Leith
Matthew J. Dowd
Aaron L. Schwartz
Katrina Yujian Pei Quach
tis Bryan L. Sekton
Id Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford
Michelle K. Holoubek
Robert H. Deselms
Simon J. Elliott

Ted J. Ebersole

Julie A. Heider Mita Mukherjee Scott M. Woodhouse Michael G. Penn Christopher J. Walsh

Of Counsel Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

December 22, 2004

WRITER'S DIRECT NUMBER:
(202) 772-8525
INTERNET ADDRESS:
BRIAND@SKGF.COM

Art Unit 1641

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/743,295; Filed: December 23, 2003

For: Polymer Conjugates of Cytokines, Chemokines, Growth Factors,

Polypeptide Hormones and Antagonists Thereof with Preserved

Receptor-Binding Activity

Inventors:

BHASKARAN et al.

Our Ref:

2057.0060002/JAG/BJD

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Third Supplemental Information Disclosure Statement;
- 2. One (1) page of Form PTO-1449 citing documents AG9 and AH9; and
- 3. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLL.C.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents December 22, 2004 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Brian J. Del Buono Attorney for Applicants Registration No. 42,473

BJD/nef Enclosures

347562_1.DOC



THE UNITED STATES PATENT AND TRADEMARK OFFICE

plication of:

Bhaskaran et al.

Appl. No.: 10/743,295

Filed: December 23, 2003

For:

Polymer Conjugates of Cytokines,

Chemokines, Growth Factors, Polypeptide Hormones and

Antagonists Thereof with Preserved

Receptor-Binding Activity

Confirmation No.: 7998

Art Unit:

1641

Examiner:

To be assigned

Atty. Docket: 2057.0060002/JAG/BJD

Third Supplemental Information Disclosure Statement

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

The numbering on this Third Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Second Supplemental Information Disclosure Statement filed December 10, 2004, in connection with the above-captioned application.

Copies of documents AG9 and AH9 are not provided in accordance with the Changes To Support Implementation of the United States Patent and Trademark Office 21st Century Strategic Plan, effective October 21, 2004, which states that "section 1.98(a)(2)(i) is amended to eliminate the requirement in paragraph (a)(2)(i) for a copy of each U.S. patent or U.S. patent application publication listed in an IDS in a patent application regardless of the filing date of the application."

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and

Bhaskaran *et al.* Appl. No. 10/743,295

any foreign priority date so that the month of publication is not in issue. Applicants have listed the

publication dates on the attached Form PTO-1449 based on information presently available to the

undersigned. However, the listed publication dates should not be construed as an admission that the

information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any

of the information provided herewith, and/or to prove that this information may not be prior art,

and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or

that information more material to the examination of the present patent application does not exist.

The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office

Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form

PTO-1449, and indicate in the official file wrapper of this patent application that the documents have

been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or

credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Brian J. Del Buono

Attorney for Applicants

Registration No. 42,473

Date: Dec (27, 707) 1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

347526_1.DOC

FORM PTO-1449

THIRD SUPPLEMENTAL

INFORMATION DISCLOSURE STATEMENT

THIRD SUPPLEMENTAL

THIRD SUPPLEMENTA

ATTY. DOCKET NO. 2057.0060002/JAG/BJD APPLICATION NO. 10/743,295

APPLICANT BHASKARAN et al.

FILING DATE December 23, 2003 GROUP 1641

U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DAT		
	AA9								
	AB9								
•	AC9								
	AD9								
=	AE9								
	AF9								
	AG9	US 2003/0219404 A1	11/27/2003	Yamasaki et al.	424	85.4	12/22/2000		
	AH9	US 2004/0249576 A1	12/09/2004	Desjarlais et al.	702	19	03/31/2004		
	AI								
	AJ								
	AK								

FOREIGN PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION		
	AL						Yes No		
	AM5						Yes No		
	AN5						Yes No		
	AO						Yes No		
	AP						Yes No		

		OTHER	(Including	Author,	Title,	Date,	Pertinent	Pages,	etc.)	
	AR									
	AS									
	AT									
EXAMINER									DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.